Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1015MR)

This product GTTS-WQ1015MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1015MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8968MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ15378MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ8855MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ13181MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ5159MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ2153MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ14845MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ9682MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64052781
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW